Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in CashFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

Goldenwell Biotech (GWLL) Free Cash Flow (2019 - 2025)

Goldenwell Biotech's Free Cash Flow history spans 7 years, with the latest figure at -$30885.0 for Q3 2025.

  • For Q3 2025, Free Cash Flow fell 47.32% year-over-year to -$30885.0; the TTM value through Sep 2025 reached -$29133.0, up 75.06%, while the annual FY2024 figure was -$123077.0, 8.77% down from the prior year.
  • Free Cash Flow reached -$30885.0 in Q3 2025 per GWLL's latest filing, down from $59380.0 in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $59380.0 in Q2 2025 to a low of -$917090.0 in Q4 2022.
  • Average Free Cash Flow over 5 years is -$86571.2, with a median of -$29010.0 recorded in 2024.
  • Peak YoY movement for Free Cash Flow: tumbled 105675.35% in 2021, then surged 224.35% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$19373.0 in 2021, then plummeted by 4633.86% to -$917090.0 in 2022, then soared by 97.92% to -$19076.0 in 2023, then plummeted by 32.89% to -$25351.0 in 2024, then decreased by 21.83% to -$30885.0 in 2025.
  • Per Business Quant, the three most recent readings for GWLL's Free Cash Flow are -$30885.0 (Q3 2025), $59380.0 (Q2 2025), and -$32277.0 (Q1 2025).